目的 分析中国医科大学附属第一医院麻醉药品的应用情况及用药趋势，为临床合理用药和科学规范管理提供依据，促进麻醉药品的合理使用。方法 收集2017-2019年中国医科大学附属第一医院住院患者麻醉药品使用的有关数据，将金额、用药频度（DDDs）、限定日费用（DDC）、排序比（B/A）等进行统计分析。结果 2017-2019年中国医科大学附属第一医院住院药房使用的麻醉药品涉及14个品规，麻醉药品的销售金额总体上呈逐年递增趋势。其中羟考酮注射液、枸橼酸舒芬太尼注射液（0.05 mg）和注射用盐酸瑞芬太尼（2 mg）的销售金额排序均稳居前3位。枸橼酸舒芬太尼注射液（0.05 mg）、麻黄碱注射液（30 mg）的DDDs连续3年排在前2位，枸橼酸芬太尼注射液（0.5 mg）的DDDs在2019年有所下降。注射用瑞芬太尼（2 mg）的DDDs在2019年有所上升。羟考酮注射液（10 mg）、注射用瑞芬太尼（2 mg）、注射用瑞芬太尼（1 mg）、枸橼酸舒芬太尼注射液（0.05 mg）的DDC值排在前4位。结论 中国医科大学附属第一医院住院患者使用麻醉药品的销售金额逐年增加，麻醉药品的使用及管理基本符合相关标准和诊疗规范，但仍需要进一步规范临床用药，加强监控与干预。

Objective To analyze the application and tendency of narcotic drugs in the First Affiliated Hospital of China Medical University, so as to provide evidence for clinical rational drug use, scientific and standardized management, and promote rational use of narcotic drugs. Methods The relevant data of narcotic drug use in the First Affiliated Hospital of China Medical University from 2017 to 2019 were collected, and the amount, dosage, DDDs, DDC, and B/A were statistically analyzed. Results From 2017 to 2019, the narcotic drugs used in the inpatient pharmacy of the First Affiliated Hospital of China Medical University involved 14 drug specifications, and the consumption sum of narcotic drugs generally showed an increasing trend year by year. Among them, the consumption sum of Oxycodone Injection, Sufentanil Citrate Injection (0.05 mg), and Remifentanil Hydrochloride for Injection (2 mg) all ranked the top 3. DDDs of Sufentanil Citrate Injection (0.05 mg) and Ephedrine Injection (30 mg) ranked first and second for three consecutive years. DDDs of Fentanyl Citrate Injection (0.5 mg) were decreased in 2019, but DDDs of Remifentanil Hydrochloride for Injection (2 mg) were increased. The DDC values of Oxycodone Injection (10 mg), Remifentanil for Injection (2 mg), Remifentanil for Injection (1 mg), and Sufentanil Citrate Injection (0.05 mg) ranked the first 4. Conclusion The sales amount of narcotic drugs used by inpatients in the First Affiliated Hospital of China Medical University has increased year by year, the use and management of narcotic drugs basically conform to the relevant standards and treatment norms, but it is still necessary to further standardize the clinical drug use and strengthen monitoring and intervention.

R971